notice Note: Please be cautious and check with your supplier if this product is for virus protection purposes and if the coronavirus (COVID-19) will affect your order. close

Free Shipping Hair Loss Treatment Setipiprant

  • 10-49 Grams
    $8.50
  • 50-99 Grams
    $7.00
  • >=100 Grams
    $6.50
Quantity:
- + Grams available
Samples:
$16.00 /Gram, 1 Gram (Min. Order): Buy Samples
0piecesselected, US $in total
View Details
Shipping fee:
Depends on the order quantity.
Lead Time:
5 day(s) after payment received
Customization:
Customized packaging (Min. Order: 500 Grams)
Contact Supplier
Samples - $16.00 /Gram, 1 Gram (Min. Order): Buy Samples
Loading... Add To Cart
Report Suspicious Activity
Overview
Quick Details
CAS No.:
866460-33-5
Other Names:
Setipiprant
MF:
C24H19FN2O3
EINECS No.:
/
Place of Origin:
Shaanxi, China
Purity:
99%min
Appearance:
White powder, White powder
Usage:
Hair Care Chemicals
Brand Name:
Lyphar
Model Number:
LY-Setipiprant
Product Name:
Setipiprant
Grade:
Pharmaceutcial Grade
Application:
Hair loss treatment
Assay:
HPLC 99%
Certificate:
ISO9001
Shelf life:
2 Years
certificate:
ISO9001
Stock:
Available
COA:
Available

Packaging & Delivery

Selling Units:
Single item
Single package size: 
17X12X10 cm
Single gross weight:
0.200 kg
Package Type:
Sealed plastic bag with aluminium foil bag outside The outer packing is paper carton
Picture Example:
package-img
Lead Time :
Quantity(Grams) 1 - 100 >100
Est. Time(days) 5 To be negotiated

Free Shipping Hair Loss Treatment Setipiprant

Other products used in hair loss treatment

Click the product name for more details

The products in stock can be sent within 1 working day after receiving the payment

Minoxidil Sulfate in stockCB-03-01

Finasteride in stock 

Minoxidil in stock 

Dutasteride in stock

WAY316606Setipiprant in stock

 

Product name: Setipiprant  
CAS NO: 866460-33-5

Purity:99%
MF :C24H19FN2O3
Grade: Medicine Grade 

Click the product name to order

Minoxidil

RU58841


 

 

Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelion which acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). It was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients, it failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.

However, following the discovery in 2012 that the prostaglandin D2 receptor (DP/PGD2) is expressed at high levels in the scalp of men affected by male pattern baldness, the rights to setipiprant were acquired by Kythera with a view to potentially developing this drug as a novel treatment for baldness, with a previously unexploited mechanism of action. While it is too early to tell whether setipiprant will be an effective treatment for this condition, the favorable pharmacokinetics and relative lack of side effects seen in earlier clinical trials mean that fresh clinical trials for this new application can be conducted fairly quickly.

A phase 2A study is underway to evaluate the safety, tolerability, and efficacy of oral setipiprant relative to a placebo and the active comparator, finasteride, in 18 to 41 years old males with androgenetic alopecia.

You May Like
Not exactly what you want? 1 request, multiple quotations Get Quotations Now >>